Literature DB >> 25728094

High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency.

Kirsten Bienemann1, Arndt Borkhardt1, Wolfram Klapper2, Ilske Oschlies2.   

Abstract

AIMS: Interleukin-2-inducible T-cell kinase (ITK) deficiency is an inherited T-cell deficiency characterized by the development of Epstein-Barr virus (EBV)-associated lymphoproliferations. We aimed to describe the histopathological features of lymphoproliferative processes arising in ITK deficiency, and to compare them with lymphoproliferations in otherwise immunocompromised patients. METHODS AND
RESULTS: We revised the histopathological diagnoses of 12 biopsies of lymphoproliferations from seven ITK-deficient children according to the World Health Organization criteria, and determined the EBV latency types and lytic activity by staining for EBV-encoded small RNA, latent membrane protein 1, EBV nuclear antigen 2, and ZEBRA. We found polymorphic and borderline polymorphic to monomorphic B-cell lymphoproliferations with variable contents in large cells (five cases), a Hodgkin-like B-cell proliferation (one case), and classic mixed-cellularity Hodgkin lymphoma (six cases). All cases (12/12) were EBV-positive. The Hodgkin lymphoma-like and Hodgkin lymphoma, and all but one polymorphic B-cell lymphoproliferation, showed EBV latency type 2, as observed in classic EBV-positive Hodgkin lymphoma.
CONCLUSIONS: The 100% EBV association, the high percentage of EBV-positive classic Hodgkin lymphoma and Hodgkin-like B-cell proliferations and the predominance of EBV latency type 2 even in polymorphic lesions are the main features of lymphoproliferations in patients with ITK deficiency, and suggest a unique pathomechanism of lymphomagenesis in this T-cell immunodeficiency.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  EBV-positive Hodgkin lymphoma; EBV-positive lymphoproliferation; Interleukin-2-inducible T-cell kinase deficiency; immunodeficiency-associated lymphoma

Mesh:

Substances:

Year:  2015        PMID: 25728094     DOI: 10.1111/his.12677

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  15 in total

1.  Compound Heterozygous Mutations of IL2-Inducible T cell Kinase in a Swedish Patient: the Importance of Early Genetic Diagnosis.

Authors:  Mingyan Fang; Hassan Abolhassani; Qiang Pan-Hammarström; Erik Sandholm; Xiao Liu; Lennart Hammarström
Journal:  J Clin Immunol       Date:  2019-02-12       Impact factor: 8.317

2.  Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.

Authors:  M Elgizouli; D M Lowe; C Speckmann; D Schubert; J Hülsdünker; Z Eskandarian; A Dudek; A Schmitt-Graeff; J Wanders; S F Jørgensen; B Fevang; U Salzer; A Nieters; S Burns; B Grimbacher
Journal:  Clin Exp Immunol       Date:  2015-11-09       Impact factor: 4.330

3.  Genetic Deficiency and Biochemical Inhibition of ITK Affect Human Th17, Treg, and Innate Lymphoid Cells.

Authors:  Ahmet Eken; Murat Cansever; Ido Somekh; Yoko Mizoguchi; Natalia Zietara; Fatma Zehra Okus; Serife Erdem; Halit Canatan; Sefika Akyol; Alper Ozcan; Musa Karakukcu; Sebastian Hollizeck; Meino Rohlfs; Ekrem Unal; Christoph Klein; Turkan Patiroglu
Journal:  J Clin Immunol       Date:  2019-04-25       Impact factor: 8.317

4.  Inherited Interleukin 2-Inducible T-Cell (ITK) Kinase Deficiency in Siblings With Epidermodysplasia Verruciformis and Hodgkin Lymphoma.

Authors:  Leila Youssefian; Hassan Vahidnezhad; Mehdi Yousefi; Amir Hossein Saeidian; Arghavan Azizpour; Andrew Touati; Neda Nikbakht; Kambiz Kamyab- Hesari; Mohammad Mahdi Adib-Sereshki; Sirous Zeinali; Behzad Mansoori; Ali Jazayeri; Razieh Karamzadeh; Paolo Fortina; Emmanuelle Jouanguy; Jean-Laurent Casanova; Jouni Uitto
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

Review 5.  Predispositions to Lymphoma: A Practical Review for Genetic Counselors.

Authors:  Morgan Similuk; V Koneti Rao; Jane Churpek; Michael Lenardo
Journal:  J Genet Couns       Date:  2016-06-06       Impact factor: 2.537

Review 6.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

7.  Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma.

Authors:  Efren Rael; Kevin Rakszawski; Kristian Koller; Michael Bayerl; Manish Butte; Hong Zheng
Journal:  Biomark Res       Date:  2016-03-09

8.  Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection.

Authors:  Kazushi Izawa; Emmanuel Martin; Claire Soudais; Julie Bruneau; David Boutboul; Rémy Rodriguez; Christelle Lenoir; Andrew D Hislop; Caroline Besson; Fabien Touzot; Capucine Picard; Isabelle Callebaut; Jean-Pierre de Villartay; Despina Moshous; Alain Fischer; Sylvain Latour
Journal:  J Exp Med       Date:  2016-12-23       Impact factor: 14.307

Review 9.  Epstein-Barr Virus-Specific Immune Control by Innate Lymphocytes.

Authors:  Christian Münz
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

10.  Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls.

Authors:  Cheng-Te Major Lin; Emily C Leibovitch; M Isabel Almira-Suarez; Steven Jacobson
Journal:  Infect Agent Cancer       Date:  2016-07-26       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.